2 Top Biotech Stocks to Buy Right Now

50
5
Favorite

2 Top Biotech Stocks to Buy Right Now

Motley Fool2021-07-21

Investing in biotechnology companies can be a risky proposition. Regulatory setbacks or negative results from clinical trials are sometimes enough to send shares falling off a cliff. But biotech ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（5）

Alfred1007
·2021-07-21
Biotech stocks need a lot of patience and follow up, one news will send you from heaven to hell, or vice versa...[傲嬌] [白眼]
Reply
Like
Report
Fold Replies
- Mess0M:
  YES In real gambling！！！the problem is that insiders‘s IFM have faster time to win you
  2021-07-22
  Reply
  Report
Skysy
·2021-07-21
Interesting
Reply
Like
Report
AndrewWong73
·2021-07-21
Vertex
Reply
1
Report
我发大财了
·2021-07-21
$Bionano Genomics(BNGO)$[USD] [USD] [USD] [USD] [USD] [USD] [USD] [USD] [USD] [USD] [USD] [USD] [USD] [USD] [USD]
Reply
2
Report
wwwwwl
·2021-07-21
Vertex!!
Reply
2
Report
Fold Replies
- ACCY:
  Wow
  2021-07-21
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2153643536?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-07-21 19:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2153643536","market":"us","top_or_hot":-1,"title":"2 Top Biotech Stocks to Buy Right Now","media":"Motley Fool","content":"<div>\n<p>Investing in biotechnology companies can be a risky proposition. Regulatory setbacks or negative results from clinical trials are sometimes enough to send shares falling off a cliff. But biotech ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/2-top-biotech-stocks-to-buy-right-now/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-21 19:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/2-top-biotech-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing in biotechnology companies can be a risky proposition. Regulatory setbacks or negative results from clinical trials are sometimes enough to send shares falling off a cliff. But biotech ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/2-top-biotech-stocks-to-buy-right-now/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VTNR","symbol_name":"顶点能源","start_time":0,"source_url":"https://www.fool.com/investing/2021/07/21/2-top-biotech-stocks-to-buy-right-now/","article_id":"2153643536","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2153643536","pubTimestamp":1626866940,"columns":[],"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Both of these companies have successfully developed breakthrough medicines.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"VTNR":"顶点能源","BIIB":"渤健公司"},"translate_title":"2大生物科技股应立即买入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":0.9,"VTNR":0.9},"content_text":"Investing in biotechnology companies can be a risky proposition. Regulatory setbacks or negative results from clinical trials are sometimes enough to send shares falling off a cliff. But biotech companies can also offer explosive growth, provided you pick the right ones. And before investing in a biotech company, it's essential to look at the financial opportunity offered by its current lineup of products (or most promising pipeline candidates), both in the short and long run.\nTwo biotechs whose lead products offer great potential are Vertex Pharmaceuticals (NASDAQ:VRTX) and Biogen (NASDAQ:BIIB). Let's see why both of these companies are worth investing in today.\n\nImage source: Getty Images.\n1. Vertex Pharmaceuticals\nBiotech giant Vertex Pharmaceuticals focuses on developing treatments for rare diseases. The company is best known for its suite of medicines that treat cystic fibrosis (CF), a potentially deadly genetic condition that affects a patient's internal organs, including the lungs and the digestive system. CF affects 75,000 people in the U.S., Australia, and Europe, and there are 1,000 new cases diagnosed in the U.S. every year.\nBecause there are more than 100 mutations of the gene that causes CF, it's been hard to develop a single medicine that can treat the entirety of this patient population. However, back in October 2019, the U.S. Food and Drug Administration (FDA) approved Vertex's Trikafta, a therapy that can treat up to 90% of CF patients.\nLast year, Trikafta generated $3.9 billion in sales and that number will rise to $8.7 billion in 2026, according to the research company Evaluate Pharma, making it among the 10 best-selling drugs in the world. With that said, there are other reasons why Vertex Pharma is a buy.\nThe company boasts several exciting pipeline programs, including CTX001, a gene-editing therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia that it's developing in collaboration with CRISPR Therapeutics. If CTX001 earns regulatory approval, it would be a major achievement since there are currently few therapy options for those two blood-related disorders. The ones that exist (including stem cell transplants) are rife with risks.\nCTX001 has shown the ability to eliminate the need for blood transfusions in TDT patients up to 26 months after treatment. It has also successfully freed SCD patients of painful side effects of the illness called vaso-occlusive crises, up to 22 months post-treatment.\nDuring the company's first-quarter earnings conference call, Vertex CEO Reshma Kewalramani said that a regulatory submission for CTX001 \"may be possible in the next 18 to 24 months.\" Vertex Pharma does have other pipeline candidates, and the company generated a little more than $3 billion in free cash flow over the past year, allowing it to acquire more promising programs from other biotechs if necessary.\nLastly, now is an excellent time to buy this stock because it has severely underperformed of late. Shares of Vertex Pharma are down 34% in the past year, while the S&P 500 is up by 31% in the same period. Vertex's current price-to-earnings (PE) ratio is 19.06 -- which is about as low as it has been in two years -- and its forward PE stands at 18.39, which is also low by its standards. At current levels, this biotech stock is definitely a buy.\n\nImage source: Getty Images.\n2. Biogen\nBiogen's prospects didn't seem so great just 12 months ago. In June 2020, a judge invalidated a patent on Biogen's multiple sclerosis (MS) drug Tecfidera. The company has been facing biosimilar competition for this product since the second half of 2020, and its sales have declined quite a bit as a result.\nLast year, it also seemed unlikely that Biogen's drug for Alzheimer's disease (AD) Aduhelm (aducanumab) would earn regulatory approval since an independent panel convened by the FDA almost unanimously voted against giving the drug the green light.\nBut against all odds, Aduhelm did earn regulatory approval, and although Tecfidera's prospects haven't changed, the AD drug alone is enough to brighten Biogen's future significantly. Note that Aduhelm is the first AD drug approved by the FDA since 2003, and it is also the first of its kind to target one of the rumored causes of this invasive illness: the accumulation of beta-amyloid protein in the brain.\nIt won't be cheap; the cost of a one-year course for the treatment will be $56,000. There are 6 million AD patients in the U.S., but the FDA emphasized that Aduhelm should be prescribed to patients with \"mild cognitive impairment or mild dementia stage of disease.\"\nEven so, Aduhelm is likely to rack up well over $1 billion in sales within the next couple of years. Biogen has many more pipeline programs, including half a dozen in late-stage studies. There is no doubt the company will look to diversify its revenue source away from Aduhelm in the coming years.\nAnd even though the biotech's shares have already benefited from the approval of the AD drug -- with its stock up by 34.1% year to date -- I believe there is significant upside left for the company, especially once sales of Aduhelm start coming in.\nBiogen's PE and forward PE are 17.05 and 17.36, respectively. While those metrics have risen for the company since the beginning of the year, they are justified by its prospects in the AD market, making Biogen's stock a buy right now.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":176634877,"gmtCreate":1626879202199,"gmtModify":1703479881035,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":2,"crmLevelSwitch":0,"idStr":"3570656625926041","authorIdStr":"3570656625926041"},"htmlText":"Biotech stocks need a lot of patience and follow up, one news will send you from heaven to hell, or vice versa...[傲嬌]&nbsp;[白眼]&nbsp;","listText":"Biotech stocks need a lot of patience and follow up, one news will send you from heaven to hell, or vice versa...[傲嬌]&nbsp;[白眼]&nbsp;","text":"Biotech stocks need a lot of patience and follow up, one news will send you from heaven to hell, or vice versa...[傲嬌] [白眼]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/176634877","repostId":2153643536,"repostType":4,"repost":{"id":"2153643536","kind":"highlight","pubTimestamp":1626866940,"share":"https://ttm.financial/m/news/2153643536?lang=&edition=fundamental","pubTime":"2021-07-21 19:29","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2153643536","media":"Motley Fool","summary":"Both of these companies have successfully developed breakthrough medicines.","content":"<p>Investing in biotechnology companies can be a risky proposition. Regulatory setbacks or negative results from clinical trials are sometimes enough to send shares falling off a cliff. But biotech companies can also offer explosive growth, provided you pick the right ones. And before investing in a biotech company, it's essential to look at the financial opportunity offered by its current lineup of products (or most promising pipeline candidates), both in the short and long run.</p>\n<p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> biotechs whose lead products offer great potential are <b><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></b> (NASDAQ:VRTX) and <b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b> (NASDAQ:BIIB). Let's see why both of these companies are worth investing in today.</p>\n<p><img src=\"https://static.tigerbbs.com/1e68b2bfcc71824b55ac1ca69d2eed8b\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>1. <a href=\"https://laohu8.com/S/VTNR\">Vertex</a> Pharmaceuticals</h3>\n<p>Biotech giant Vertex Pharmaceuticals focuses on developing treatments for rare diseases. The company is best known for its suite of medicines that treat cystic fibrosis (CF), a potentially deadly genetic condition that affects a patient's internal organs, including the lungs and the digestive system. CF affects 75,000 people in the U.S., Australia, and Europe, and there are 1,000 new cases diagnosed in the U.S. every year.</p>\n<p>Because there are more than 100 mutations of the gene that causes CF,&nbsp;it's been hard to develop a single medicine that can treat the entirety of this patient population. However, back in October 2019, the U.S. Food and Drug Administration (FDA) approved Vertex's Trikafta, a therapy that can treat up to 90% of CF patients.</p>\n<p>Last year, Trikafta generated $3.9 billion in sales and that number will rise to $8.7 billion in 2026, according to the research company Evaluate Pharma, making it among the 10 best-selling drugs in the world. With that said, there are other reasons why Vertex Pharma is a buy.</p>\n<p>The company boasts several exciting pipeline programs, including CTX001, a gene-editing therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia that it's developing in collaboration with <b>CRISPR Therapeutics</b>. If CTX001 earns regulatory approval, it would be a major achievement since there are currently few therapy options for those two blood-related disorders. The ones that exist (including stem cell transplants) are rife with risks.</p>\n<p>CTX001 has shown the ability to eliminate the need for blood transfusions in TDT patients up to 26 months after treatment. It has also successfully freed SCD patients of painful side effects of the illness called vaso-occlusive crises, up to 22 months post-treatment.</p>\n<p>During the company's first-quarter earnings conference call, Vertex CEO Reshma Kewalramani said that a regulatory submission for CTX001 \"may be possible in the next 18 to 24 months.\" Vertex Pharma does have other pipeline candidates, and the company generated a little more than $3 billion in free cash flow over the past year, allowing it to acquire more promising programs from other biotechs if necessary.</p>\n<p>Lastly, now is an excellent time to buy this stock because it has severely underperformed of late. Shares of Vertex Pharma are down 34% in the past year, while the <b>S&amp;P 500</b> is up by 31% in the same period. Vertex's current price-to-earnings (PE) ratio is 19.06 -- which is about as low as it has been in two years -- and its forward PE stands at 18.39, which is also low by its standards. At current levels, this biotech stock is definitely a buy.</p>\n<p><img src=\"https://static.tigerbbs.com/198a83aa9d0f757fa77165d137b17531\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>2. Biogen</h3>\n<p>Biogen's prospects didn't seem so great just 12 months ago. In June 2020, a judge invalidated a patent on Biogen's multiple sclerosis (MS) drug Tecfidera. The company has been facing biosimilar competition for this product since the second half of 2020, and its sales have declined quite a bit as a result.</p>\n<p>Last year, it also seemed unlikely that Biogen's drug for Alzheimer's disease (AD) Aduhelm (aducanumab) would earn regulatory approval since an independent panel convened by the FDA almost unanimously voted against giving the drug the green light.</p>\n<p>But against all odds, Aduhelm did earn regulatory approval, and although Tecfidera's prospects haven't changed, the AD drug alone is enough to brighten Biogen's future significantly. Note that Aduhelm is the first AD drug approved by the FDA since 2003, and it is also the first of its kind to target <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the rumored causes of this invasive illness: the accumulation of beta-amyloid protein in the brain.</p>\n<p>It won't be cheap; the cost of a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-year course for the treatment will be $56,000. There are 6 million AD patients in the U.S., but the FDA emphasized that Aduhelm should be prescribed to patients with \"mild cognitive impairment or mild dementia stage of disease.\"</p>\n<p>Even so, Aduhelm is likely to rack up well over $1 billion in sales within the next couple of years. Biogen has many more pipeline programs, including half a dozen in late-stage studies.&nbsp;There is no doubt the company will look to diversify its revenue source away from Aduhelm in the coming years.</p>\n<p>And even though the biotech's shares have already benefited from the approval of the AD drug -- with its stock up by 34.1% year to date -- I believe there is significant upside left for the company, especially once sales of Aduhelm start coming in.</p>\n<p>Biogen's PE and forward PE are 17.05 and 17.36, respectively. While those metrics have risen for the company since the beginning of the year, they are justified by its prospects in the AD market, making Biogen's stock a buy right now.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-21 19:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/2-top-biotech-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing in biotechnology companies can be a risky proposition. Regulatory setbacks or negative results from clinical trials are sometimes enough to send shares falling off a cliff. But biotech ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/2-top-biotech-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司","VTNR":"顶点能源"},"source_url":"https://www.fool.com/investing/2021/07/21/2-top-biotech-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153643536","content_text":"Investing in biotechnology companies can be a risky proposition. Regulatory setbacks or negative results from clinical trials are sometimes enough to send shares falling off a cliff. But biotech companies can also offer explosive growth, provided you pick the right ones. And before investing in a biotech company, it's essential to look at the financial opportunity offered by its current lineup of products (or most promising pipeline candidates), both in the short and long run.\nTwo biotechs whose lead products offer great potential are Vertex Pharmaceuticals (NASDAQ:VRTX) and Biogen (NASDAQ:BIIB). Let's see why both of these companies are worth investing in today.\n\nImage source: Getty Images.\n1. Vertex Pharmaceuticals\nBiotech giant Vertex Pharmaceuticals focuses on developing treatments for rare diseases. The company is best known for its suite of medicines that treat cystic fibrosis (CF), a potentially deadly genetic condition that affects a patient's internal organs, including the lungs and the digestive system. CF affects 75,000 people in the U.S., Australia, and Europe, and there are 1,000 new cases diagnosed in the U.S. every year.\nBecause there are more than 100 mutations of the gene that causes CF, it's been hard to develop a single medicine that can treat the entirety of this patient population. However, back in October 2019, the U.S. Food and Drug Administration (FDA) approved Vertex's Trikafta, a therapy that can treat up to 90% of CF patients.\nLast year, Trikafta generated $3.9 billion in sales and that number will rise to $8.7 billion in 2026, according to the research company Evaluate Pharma, making it among the 10 best-selling drugs in the world. With that said, there are other reasons why Vertex Pharma is a buy.\nThe company boasts several exciting pipeline programs, including CTX001, a gene-editing therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia that it's developing in collaboration with CRISPR Therapeutics. If CTX001 earns regulatory approval, it would be a major achievement since there are currently few therapy options for those two blood-related disorders. The ones that exist (including stem cell transplants) are rife with risks.\nCTX001 has shown the ability to eliminate the need for blood transfusions in TDT patients up to 26 months after treatment. It has also successfully freed SCD patients of painful side effects of the illness called vaso-occlusive crises, up to 22 months post-treatment.\nDuring the company's first-quarter earnings conference call, Vertex CEO Reshma Kewalramani said that a regulatory submission for CTX001 \"may be possible in the next 18 to 24 months.\" Vertex Pharma does have other pipeline candidates, and the company generated a little more than $3 billion in free cash flow over the past year, allowing it to acquire more promising programs from other biotechs if necessary.\nLastly, now is an excellent time to buy this stock because it has severely underperformed of late. Shares of Vertex Pharma are down 34% in the past year, while the S&P 500 is up by 31% in the same period. Vertex's current price-to-earnings (PE) ratio is 19.06 -- which is about as low as it has been in two years -- and its forward PE stands at 18.39, which is also low by its standards. At current levels, this biotech stock is definitely a buy.\n\nImage source: Getty Images.\n2. Biogen\nBiogen's prospects didn't seem so great just 12 months ago. In June 2020, a judge invalidated a patent on Biogen's multiple sclerosis (MS) drug Tecfidera. The company has been facing biosimilar competition for this product since the second half of 2020, and its sales have declined quite a bit as a result.\nLast year, it also seemed unlikely that Biogen's drug for Alzheimer's disease (AD) Aduhelm (aducanumab) would earn regulatory approval since an independent panel convened by the FDA almost unanimously voted against giving the drug the green light.\nBut against all odds, Aduhelm did earn regulatory approval, and although Tecfidera's prospects haven't changed, the AD drug alone is enough to brighten Biogen's future significantly. Note that Aduhelm is the first AD drug approved by the FDA since 2003, and it is also the first of its kind to target one of the rumored causes of this invasive illness: the accumulation of beta-amyloid protein in the brain.\nIt won't be cheap; the cost of a one-year course for the treatment will be $56,000. There are 6 million AD patients in the U.S., but the FDA emphasized that Aduhelm should be prescribed to patients with \"mild cognitive impairment or mild dementia stage of disease.\"\nEven so, Aduhelm is likely to rack up well over $1 billion in sales within the next couple of years. Biogen has many more pipeline programs, including half a dozen in late-stage studies. There is no doubt the company will look to diversify its revenue source away from Aduhelm in the coming years.\nAnd even though the biotech's shares have already benefited from the approval of the AD drug -- with its stock up by 34.1% year to date -- I believe there is significant upside left for the company, especially once sales of Aduhelm start coming in.\nBiogen's PE and forward PE are 17.05 and 17.36, respectively. While those metrics have risen for the company since the beginning of the year, they are justified by its prospects in the AD market, making Biogen's stock a buy right now.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5291492,"gmtCreate":1626935668057,"gmtModify":1663231312543,"authorId":3479274802108413,"author":{"id":3479274802108413,"idStr":"3479274802108413","authorId":3479274802108413,"name":"Mess0M","avatar":"https://static.tigerbbs.com/6f40081eb0713a23c3646b1838cc62f7","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":176634877,"type":1,"supId":0,"prevId":0,"content":"YES In real gambling！！！the problem is that  insiders‘s IFM have faster time to win  you","text":"YES In real gambling！！！the problem is that  insiders‘s IFM have faster time to win  you","html":"YES In real gambling！！！the problem is that  insiders‘s IFM have faster time to win  you"}],"langContent":"CN"},{"id":176832032,"gmtCreate":1626875607326,"gmtModify":1703479735447,"author":{"id":"3580721209853601","authorId":"3580721209853601","name":"Skysy","avatar":"https://static.tigerbbs.com/f440b8692274a0da19e634034c3f28e5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3580721209853601","authorIdStr":"3580721209853601"},"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/176832032","repostId":2153643536,"repostType":4,"repost":{"id":"2153643536","kind":"highlight","pubTimestamp":1626866940,"share":"https://ttm.financial/m/news/2153643536?lang=&edition=fundamental","pubTime":"2021-07-21 19:29","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2153643536","media":"Motley Fool","summary":"Both of these companies have successfully developed breakthrough medicines.","content":"<p>Investing in biotechnology companies can be a risky proposition. Regulatory setbacks or negative results from clinical trials are sometimes enough to send shares falling off a cliff. But biotech companies can also offer explosive growth, provided you pick the right ones. And before investing in a biotech company, it's essential to look at the financial opportunity offered by its current lineup of products (or most promising pipeline candidates), both in the short and long run.</p>\n<p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> biotechs whose lead products offer great potential are <b><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></b> (NASDAQ:VRTX) and <b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b> (NASDAQ:BIIB). Let's see why both of these companies are worth investing in today.</p>\n<p><img src=\"https://static.tigerbbs.com/1e68b2bfcc71824b55ac1ca69d2eed8b\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>1. <a href=\"https://laohu8.com/S/VTNR\">Vertex</a> Pharmaceuticals</h3>\n<p>Biotech giant Vertex Pharmaceuticals focuses on developing treatments for rare diseases. The company is best known for its suite of medicines that treat cystic fibrosis (CF), a potentially deadly genetic condition that affects a patient's internal organs, including the lungs and the digestive system. CF affects 75,000 people in the U.S., Australia, and Europe, and there are 1,000 new cases diagnosed in the U.S. every year.</p>\n<p>Because there are more than 100 mutations of the gene that causes CF,&nbsp;it's been hard to develop a single medicine that can treat the entirety of this patient population. However, back in October 2019, the U.S. Food and Drug Administration (FDA) approved Vertex's Trikafta, a therapy that can treat up to 90% of CF patients.</p>\n<p>Last year, Trikafta generated $3.9 billion in sales and that number will rise to $8.7 billion in 2026, according to the research company Evaluate Pharma, making it among the 10 best-selling drugs in the world. With that said, there are other reasons why Vertex Pharma is a buy.</p>\n<p>The company boasts several exciting pipeline programs, including CTX001, a gene-editing therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia that it's developing in collaboration with <b>CRISPR Therapeutics</b>. If CTX001 earns regulatory approval, it would be a major achievement since there are currently few therapy options for those two blood-related disorders. The ones that exist (including stem cell transplants) are rife with risks.</p>\n<p>CTX001 has shown the ability to eliminate the need for blood transfusions in TDT patients up to 26 months after treatment. It has also successfully freed SCD patients of painful side effects of the illness called vaso-occlusive crises, up to 22 months post-treatment.</p>\n<p>During the company's first-quarter earnings conference call, Vertex CEO Reshma Kewalramani said that a regulatory submission for CTX001 \"may be possible in the next 18 to 24 months.\" Vertex Pharma does have other pipeline candidates, and the company generated a little more than $3 billion in free cash flow over the past year, allowing it to acquire more promising programs from other biotechs if necessary.</p>\n<p>Lastly, now is an excellent time to buy this stock because it has severely underperformed of late. Shares of Vertex Pharma are down 34% in the past year, while the <b>S&amp;P 500</b> is up by 31% in the same period. Vertex's current price-to-earnings (PE) ratio is 19.06 -- which is about as low as it has been in two years -- and its forward PE stands at 18.39, which is also low by its standards. At current levels, this biotech stock is definitely a buy.</p>\n<p><img src=\"https://static.tigerbbs.com/198a83aa9d0f757fa77165d137b17531\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>2. Biogen</h3>\n<p>Biogen's prospects didn't seem so great just 12 months ago. In June 2020, a judge invalidated a patent on Biogen's multiple sclerosis (MS) drug Tecfidera. The company has been facing biosimilar competition for this product since the second half of 2020, and its sales have declined quite a bit as a result.</p>\n<p>Last year, it also seemed unlikely that Biogen's drug for Alzheimer's disease (AD) Aduhelm (aducanumab) would earn regulatory approval since an independent panel convened by the FDA almost unanimously voted against giving the drug the green light.</p>\n<p>But against all odds, Aduhelm did earn regulatory approval, and although Tecfidera's prospects haven't changed, the AD drug alone is enough to brighten Biogen's future significantly. Note that Aduhelm is the first AD drug approved by the FDA since 2003, and it is also the first of its kind to target <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the rumored causes of this invasive illness: the accumulation of beta-amyloid protein in the brain.</p>\n<p>It won't be cheap; the cost of a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-year course for the treatment will be $56,000. There are 6 million AD patients in the U.S., but the FDA emphasized that Aduhelm should be prescribed to patients with \"mild cognitive impairment or mild dementia stage of disease.\"</p>\n<p>Even so, Aduhelm is likely to rack up well over $1 billion in sales within the next couple of years. Biogen has many more pipeline programs, including half a dozen in late-stage studies.&nbsp;There is no doubt the company will look to diversify its revenue source away from Aduhelm in the coming years.</p>\n<p>And even though the biotech's shares have already benefited from the approval of the AD drug -- with its stock up by 34.1% year to date -- I believe there is significant upside left for the company, especially once sales of Aduhelm start coming in.</p>\n<p>Biogen's PE and forward PE are 17.05 and 17.36, respectively. While those metrics have risen for the company since the beginning of the year, they are justified by its prospects in the AD market, making Biogen's stock a buy right now.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-21 19:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/2-top-biotech-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing in biotechnology companies can be a risky proposition. Regulatory setbacks or negative results from clinical trials are sometimes enough to send shares falling off a cliff. But biotech ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/2-top-biotech-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司","VTNR":"顶点能源"},"source_url":"https://www.fool.com/investing/2021/07/21/2-top-biotech-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153643536","content_text":"Investing in biotechnology companies can be a risky proposition. Regulatory setbacks or negative results from clinical trials are sometimes enough to send shares falling off a cliff. But biotech companies can also offer explosive growth, provided you pick the right ones. And before investing in a biotech company, it's essential to look at the financial opportunity offered by its current lineup of products (or most promising pipeline candidates), both in the short and long run.\nTwo biotechs whose lead products offer great potential are Vertex Pharmaceuticals (NASDAQ:VRTX) and Biogen (NASDAQ:BIIB). Let's see why both of these companies are worth investing in today.\n\nImage source: Getty Images.\n1. Vertex Pharmaceuticals\nBiotech giant Vertex Pharmaceuticals focuses on developing treatments for rare diseases. The company is best known for its suite of medicines that treat cystic fibrosis (CF), a potentially deadly genetic condition that affects a patient's internal organs, including the lungs and the digestive system. CF affects 75,000 people in the U.S., Australia, and Europe, and there are 1,000 new cases diagnosed in the U.S. every year.\nBecause there are more than 100 mutations of the gene that causes CF, it's been hard to develop a single medicine that can treat the entirety of this patient population. However, back in October 2019, the U.S. Food and Drug Administration (FDA) approved Vertex's Trikafta, a therapy that can treat up to 90% of CF patients.\nLast year, Trikafta generated $3.9 billion in sales and that number will rise to $8.7 billion in 2026, according to the research company Evaluate Pharma, making it among the 10 best-selling drugs in the world. With that said, there are other reasons why Vertex Pharma is a buy.\nThe company boasts several exciting pipeline programs, including CTX001, a gene-editing therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia that it's developing in collaboration with CRISPR Therapeutics. If CTX001 earns regulatory approval, it would be a major achievement since there are currently few therapy options for those two blood-related disorders. The ones that exist (including stem cell transplants) are rife with risks.\nCTX001 has shown the ability to eliminate the need for blood transfusions in TDT patients up to 26 months after treatment. It has also successfully freed SCD patients of painful side effects of the illness called vaso-occlusive crises, up to 22 months post-treatment.\nDuring the company's first-quarter earnings conference call, Vertex CEO Reshma Kewalramani said that a regulatory submission for CTX001 \"may be possible in the next 18 to 24 months.\" Vertex Pharma does have other pipeline candidates, and the company generated a little more than $3 billion in free cash flow over the past year, allowing it to acquire more promising programs from other biotechs if necessary.\nLastly, now is an excellent time to buy this stock because it has severely underperformed of late. Shares of Vertex Pharma are down 34% in the past year, while the S&P 500 is up by 31% in the same period. Vertex's current price-to-earnings (PE) ratio is 19.06 -- which is about as low as it has been in two years -- and its forward PE stands at 18.39, which is also low by its standards. At current levels, this biotech stock is definitely a buy.\n\nImage source: Getty Images.\n2. Biogen\nBiogen's prospects didn't seem so great just 12 months ago. In June 2020, a judge invalidated a patent on Biogen's multiple sclerosis (MS) drug Tecfidera. The company has been facing biosimilar competition for this product since the second half of 2020, and its sales have declined quite a bit as a result.\nLast year, it also seemed unlikely that Biogen's drug for Alzheimer's disease (AD) Aduhelm (aducanumab) would earn regulatory approval since an independent panel convened by the FDA almost unanimously voted against giving the drug the green light.\nBut against all odds, Aduhelm did earn regulatory approval, and although Tecfidera's prospects haven't changed, the AD drug alone is enough to brighten Biogen's future significantly. Note that Aduhelm is the first AD drug approved by the FDA since 2003, and it is also the first of its kind to target one of the rumored causes of this invasive illness: the accumulation of beta-amyloid protein in the brain.\nIt won't be cheap; the cost of a one-year course for the treatment will be $56,000. There are 6 million AD patients in the U.S., but the FDA emphasized that Aduhelm should be prescribed to patients with \"mild cognitive impairment or mild dementia stage of disease.\"\nEven so, Aduhelm is likely to rack up well over $1 billion in sales within the next couple of years. Biogen has many more pipeline programs, including half a dozen in late-stage studies. There is no doubt the company will look to diversify its revenue source away from Aduhelm in the coming years.\nAnd even though the biotech's shares have already benefited from the approval of the AD drug -- with its stock up by 34.1% year to date -- I believe there is significant upside left for the company, especially once sales of Aduhelm start coming in.\nBiogen's PE and forward PE are 17.05 and 17.36, respectively. While those metrics have risen for the company since the beginning of the year, they are justified by its prospects in the AD market, making Biogen's stock a buy right now.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":176104582,"gmtCreate":1626869099146,"gmtModify":1703479563956,"author":{"id":"4088154571981280","authorId":"4088154571981280","name":"AndrewWong73","avatar":"https://static.tigerbbs.com/3ef39f6f89c0de4b2113333119e27ae2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4088154571981280","authorIdStr":"4088154571981280"},"htmlText":"Vertex&nbsp;","listText":"Vertex&nbsp;","text":"Vertex","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/176104582","repostId":2153643536,"repostType":4,"repost":{"id":"2153643536","kind":"highlight","pubTimestamp":1626866940,"share":"https://ttm.financial/m/news/2153643536?lang=&edition=fundamental","pubTime":"2021-07-21 19:29","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2153643536","media":"Motley Fool","summary":"Both of these companies have successfully developed breakthrough medicines.","content":"<p>Investing in biotechnology companies can be a risky proposition. Regulatory setbacks or negative results from clinical trials are sometimes enough to send shares falling off a cliff. But biotech companies can also offer explosive growth, provided you pick the right ones. And before investing in a biotech company, it's essential to look at the financial opportunity offered by its current lineup of products (or most promising pipeline candidates), both in the short and long run.</p>\n<p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> biotechs whose lead products offer great potential are <b><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></b> (NASDAQ:VRTX) and <b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b> (NASDAQ:BIIB). Let's see why both of these companies are worth investing in today.</p>\n<p><img src=\"https://static.tigerbbs.com/1e68b2bfcc71824b55ac1ca69d2eed8b\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>1. <a href=\"https://laohu8.com/S/VTNR\">Vertex</a> Pharmaceuticals</h3>\n<p>Biotech giant Vertex Pharmaceuticals focuses on developing treatments for rare diseases. The company is best known for its suite of medicines that treat cystic fibrosis (CF), a potentially deadly genetic condition that affects a patient's internal organs, including the lungs and the digestive system. CF affects 75,000 people in the U.S., Australia, and Europe, and there are 1,000 new cases diagnosed in the U.S. every year.</p>\n<p>Because there are more than 100 mutations of the gene that causes CF,&nbsp;it's been hard to develop a single medicine that can treat the entirety of this patient population. However, back in October 2019, the U.S. Food and Drug Administration (FDA) approved Vertex's Trikafta, a therapy that can treat up to 90% of CF patients.</p>\n<p>Last year, Trikafta generated $3.9 billion in sales and that number will rise to $8.7 billion in 2026, according to the research company Evaluate Pharma, making it among the 10 best-selling drugs in the world. With that said, there are other reasons why Vertex Pharma is a buy.</p>\n<p>The company boasts several exciting pipeline programs, including CTX001, a gene-editing therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia that it's developing in collaboration with <b>CRISPR Therapeutics</b>. If CTX001 earns regulatory approval, it would be a major achievement since there are currently few therapy options for those two blood-related disorders. The ones that exist (including stem cell transplants) are rife with risks.</p>\n<p>CTX001 has shown the ability to eliminate the need for blood transfusions in TDT patients up to 26 months after treatment. It has also successfully freed SCD patients of painful side effects of the illness called vaso-occlusive crises, up to 22 months post-treatment.</p>\n<p>During the company's first-quarter earnings conference call, Vertex CEO Reshma Kewalramani said that a regulatory submission for CTX001 \"may be possible in the next 18 to 24 months.\" Vertex Pharma does have other pipeline candidates, and the company generated a little more than $3 billion in free cash flow over the past year, allowing it to acquire more promising programs from other biotechs if necessary.</p>\n<p>Lastly, now is an excellent time to buy this stock because it has severely underperformed of late. Shares of Vertex Pharma are down 34% in the past year, while the <b>S&amp;P 500</b> is up by 31% in the same period. Vertex's current price-to-earnings (PE) ratio is 19.06 -- which is about as low as it has been in two years -- and its forward PE stands at 18.39, which is also low by its standards. At current levels, this biotech stock is definitely a buy.</p>\n<p><img src=\"https://static.tigerbbs.com/198a83aa9d0f757fa77165d137b17531\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>2. Biogen</h3>\n<p>Biogen's prospects didn't seem so great just 12 months ago. In June 2020, a judge invalidated a patent on Biogen's multiple sclerosis (MS) drug Tecfidera. The company has been facing biosimilar competition for this product since the second half of 2020, and its sales have declined quite a bit as a result.</p>\n<p>Last year, it also seemed unlikely that Biogen's drug for Alzheimer's disease (AD) Aduhelm (aducanumab) would earn regulatory approval since an independent panel convened by the FDA almost unanimously voted against giving the drug the green light.</p>\n<p>But against all odds, Aduhelm did earn regulatory approval, and although Tecfidera's prospects haven't changed, the AD drug alone is enough to brighten Biogen's future significantly. Note that Aduhelm is the first AD drug approved by the FDA since 2003, and it is also the first of its kind to target <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the rumored causes of this invasive illness: the accumulation of beta-amyloid protein in the brain.</p>\n<p>It won't be cheap; the cost of a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-year course for the treatment will be $56,000. There are 6 million AD patients in the U.S., but the FDA emphasized that Aduhelm should be prescribed to patients with \"mild cognitive impairment or mild dementia stage of disease.\"</p>\n<p>Even so, Aduhelm is likely to rack up well over $1 billion in sales within the next couple of years. Biogen has many more pipeline programs, including half a dozen in late-stage studies.&nbsp;There is no doubt the company will look to diversify its revenue source away from Aduhelm in the coming years.</p>\n<p>And even though the biotech's shares have already benefited from the approval of the AD drug -- with its stock up by 34.1% year to date -- I believe there is significant upside left for the company, especially once sales of Aduhelm start coming in.</p>\n<p>Biogen's PE and forward PE are 17.05 and 17.36, respectively. While those metrics have risen for the company since the beginning of the year, they are justified by its prospects in the AD market, making Biogen's stock a buy right now.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-21 19:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/2-top-biotech-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing in biotechnology companies can be a risky proposition. Regulatory setbacks or negative results from clinical trials are sometimes enough to send shares falling off a cliff. But biotech ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/2-top-biotech-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司","VTNR":"顶点能源"},"source_url":"https://www.fool.com/investing/2021/07/21/2-top-biotech-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153643536","content_text":"Investing in biotechnology companies can be a risky proposition. Regulatory setbacks or negative results from clinical trials are sometimes enough to send shares falling off a cliff. But biotech companies can also offer explosive growth, provided you pick the right ones. And before investing in a biotech company, it's essential to look at the financial opportunity offered by its current lineup of products (or most promising pipeline candidates), both in the short and long run.\nTwo biotechs whose lead products offer great potential are Vertex Pharmaceuticals (NASDAQ:VRTX) and Biogen (NASDAQ:BIIB). Let's see why both of these companies are worth investing in today.\n\nImage source: Getty Images.\n1. Vertex Pharmaceuticals\nBiotech giant Vertex Pharmaceuticals focuses on developing treatments for rare diseases. The company is best known for its suite of medicines that treat cystic fibrosis (CF), a potentially deadly genetic condition that affects a patient's internal organs, including the lungs and the digestive system. CF affects 75,000 people in the U.S., Australia, and Europe, and there are 1,000 new cases diagnosed in the U.S. every year.\nBecause there are more than 100 mutations of the gene that causes CF, it's been hard to develop a single medicine that can treat the entirety of this patient population. However, back in October 2019, the U.S. Food and Drug Administration (FDA) approved Vertex's Trikafta, a therapy that can treat up to 90% of CF patients.\nLast year, Trikafta generated $3.9 billion in sales and that number will rise to $8.7 billion in 2026, according to the research company Evaluate Pharma, making it among the 10 best-selling drugs in the world. With that said, there are other reasons why Vertex Pharma is a buy.\nThe company boasts several exciting pipeline programs, including CTX001, a gene-editing therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia that it's developing in collaboration with CRISPR Therapeutics. If CTX001 earns regulatory approval, it would be a major achievement since there are currently few therapy options for those two blood-related disorders. The ones that exist (including stem cell transplants) are rife with risks.\nCTX001 has shown the ability to eliminate the need for blood transfusions in TDT patients up to 26 months after treatment. It has also successfully freed SCD patients of painful side effects of the illness called vaso-occlusive crises, up to 22 months post-treatment.\nDuring the company's first-quarter earnings conference call, Vertex CEO Reshma Kewalramani said that a regulatory submission for CTX001 \"may be possible in the next 18 to 24 months.\" Vertex Pharma does have other pipeline candidates, and the company generated a little more than $3 billion in free cash flow over the past year, allowing it to acquire more promising programs from other biotechs if necessary.\nLastly, now is an excellent time to buy this stock because it has severely underperformed of late. Shares of Vertex Pharma are down 34% in the past year, while the S&P 500 is up by 31% in the same period. Vertex's current price-to-earnings (PE) ratio is 19.06 -- which is about as low as it has been in two years -- and its forward PE stands at 18.39, which is also low by its standards. At current levels, this biotech stock is definitely a buy.\n\nImage source: Getty Images.\n2. Biogen\nBiogen's prospects didn't seem so great just 12 months ago. In June 2020, a judge invalidated a patent on Biogen's multiple sclerosis (MS) drug Tecfidera. The company has been facing biosimilar competition for this product since the second half of 2020, and its sales have declined quite a bit as a result.\nLast year, it also seemed unlikely that Biogen's drug for Alzheimer's disease (AD) Aduhelm (aducanumab) would earn regulatory approval since an independent panel convened by the FDA almost unanimously voted against giving the drug the green light.\nBut against all odds, Aduhelm did earn regulatory approval, and although Tecfidera's prospects haven't changed, the AD drug alone is enough to brighten Biogen's future significantly. Note that Aduhelm is the first AD drug approved by the FDA since 2003, and it is also the first of its kind to target one of the rumored causes of this invasive illness: the accumulation of beta-amyloid protein in the brain.\nIt won't be cheap; the cost of a one-year course for the treatment will be $56,000. There are 6 million AD patients in the U.S., but the FDA emphasized that Aduhelm should be prescribed to patients with \"mild cognitive impairment or mild dementia stage of disease.\"\nEven so, Aduhelm is likely to rack up well over $1 billion in sales within the next couple of years. Biogen has many more pipeline programs, including half a dozen in late-stage studies. There is no doubt the company will look to diversify its revenue source away from Aduhelm in the coming years.\nAnd even though the biotech's shares have already benefited from the approval of the AD drug -- with its stock up by 34.1% year to date -- I believe there is significant upside left for the company, especially once sales of Aduhelm start coming in.\nBiogen's PE and forward PE are 17.05 and 17.36, respectively. While those metrics have risen for the company since the beginning of the year, they are justified by its prospects in the AD market, making Biogen's stock a buy right now.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":176371260,"gmtCreate":1626867581650,"gmtModify":1703479543172,"author":{"id":"3575408338074495","authorId":"3575408338074495","name":"我发大财了","avatar":"https://community-static.tradeup.com/news/850ce10f8979981b703d0999ccb63c31","vip":1,"crmLevel":7,"crmLevelSwitch":1,"idStr":"3575408338074495","authorIdStr":"3575408338074495"},"htmlText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;","listText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;[USD]&nbsp;","text":"$Bionano Genomics(BNGO)$[USD] [USD] [USD] [USD] [USD] [USD] [USD] [USD] [USD] [USD] [USD] [USD] [USD] [USD] [USD]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/176371260","repostId":2153643536,"repostType":4,"repost":{"id":"2153643536","kind":"highlight","pubTimestamp":1626866940,"share":"https://ttm.financial/m/news/2153643536?lang=&edition=fundamental","pubTime":"2021-07-21 19:29","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2153643536","media":"Motley Fool","summary":"Both of these companies have successfully developed breakthrough medicines.","content":"<p>Investing in biotechnology companies can be a risky proposition. Regulatory setbacks or negative results from clinical trials are sometimes enough to send shares falling off a cliff. But biotech companies can also offer explosive growth, provided you pick the right ones. And before investing in a biotech company, it's essential to look at the financial opportunity offered by its current lineup of products (or most promising pipeline candidates), both in the short and long run.</p>\n<p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> biotechs whose lead products offer great potential are <b><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></b> (NASDAQ:VRTX) and <b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b> (NASDAQ:BIIB). Let's see why both of these companies are worth investing in today.</p>\n<p><img src=\"https://static.tigerbbs.com/1e68b2bfcc71824b55ac1ca69d2eed8b\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>1. <a href=\"https://laohu8.com/S/VTNR\">Vertex</a> Pharmaceuticals</h3>\n<p>Biotech giant Vertex Pharmaceuticals focuses on developing treatments for rare diseases. The company is best known for its suite of medicines that treat cystic fibrosis (CF), a potentially deadly genetic condition that affects a patient's internal organs, including the lungs and the digestive system. CF affects 75,000 people in the U.S., Australia, and Europe, and there are 1,000 new cases diagnosed in the U.S. every year.</p>\n<p>Because there are more than 100 mutations of the gene that causes CF,&nbsp;it's been hard to develop a single medicine that can treat the entirety of this patient population. However, back in October 2019, the U.S. Food and Drug Administration (FDA) approved Vertex's Trikafta, a therapy that can treat up to 90% of CF patients.</p>\n<p>Last year, Trikafta generated $3.9 billion in sales and that number will rise to $8.7 billion in 2026, according to the research company Evaluate Pharma, making it among the 10 best-selling drugs in the world. With that said, there are other reasons why Vertex Pharma is a buy.</p>\n<p>The company boasts several exciting pipeline programs, including CTX001, a gene-editing therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia that it's developing in collaboration with <b>CRISPR Therapeutics</b>. If CTX001 earns regulatory approval, it would be a major achievement since there are currently few therapy options for those two blood-related disorders. The ones that exist (including stem cell transplants) are rife with risks.</p>\n<p>CTX001 has shown the ability to eliminate the need for blood transfusions in TDT patients up to 26 months after treatment. It has also successfully freed SCD patients of painful side effects of the illness called vaso-occlusive crises, up to 22 months post-treatment.</p>\n<p>During the company's first-quarter earnings conference call, Vertex CEO Reshma Kewalramani said that a regulatory submission for CTX001 \"may be possible in the next 18 to 24 months.\" Vertex Pharma does have other pipeline candidates, and the company generated a little more than $3 billion in free cash flow over the past year, allowing it to acquire more promising programs from other biotechs if necessary.</p>\n<p>Lastly, now is an excellent time to buy this stock because it has severely underperformed of late. Shares of Vertex Pharma are down 34% in the past year, while the <b>S&amp;P 500</b> is up by 31% in the same period. Vertex's current price-to-earnings (PE) ratio is 19.06 -- which is about as low as it has been in two years -- and its forward PE stands at 18.39, which is also low by its standards. At current levels, this biotech stock is definitely a buy.</p>\n<p><img src=\"https://static.tigerbbs.com/198a83aa9d0f757fa77165d137b17531\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>2. Biogen</h3>\n<p>Biogen's prospects didn't seem so great just 12 months ago. In June 2020, a judge invalidated a patent on Biogen's multiple sclerosis (MS) drug Tecfidera. The company has been facing biosimilar competition for this product since the second half of 2020, and its sales have declined quite a bit as a result.</p>\n<p>Last year, it also seemed unlikely that Biogen's drug for Alzheimer's disease (AD) Aduhelm (aducanumab) would earn regulatory approval since an independent panel convened by the FDA almost unanimously voted against giving the drug the green light.</p>\n<p>But against all odds, Aduhelm did earn regulatory approval, and although Tecfidera's prospects haven't changed, the AD drug alone is enough to brighten Biogen's future significantly. Note that Aduhelm is the first AD drug approved by the FDA since 2003, and it is also the first of its kind to target <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the rumored causes of this invasive illness: the accumulation of beta-amyloid protein in the brain.</p>\n<p>It won't be cheap; the cost of a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-year course for the treatment will be $56,000. There are 6 million AD patients in the U.S., but the FDA emphasized that Aduhelm should be prescribed to patients with \"mild cognitive impairment or mild dementia stage of disease.\"</p>\n<p>Even so, Aduhelm is likely to rack up well over $1 billion in sales within the next couple of years. Biogen has many more pipeline programs, including half a dozen in late-stage studies.&nbsp;There is no doubt the company will look to diversify its revenue source away from Aduhelm in the coming years.</p>\n<p>And even though the biotech's shares have already benefited from the approval of the AD drug -- with its stock up by 34.1% year to date -- I believe there is significant upside left for the company, especially once sales of Aduhelm start coming in.</p>\n<p>Biogen's PE and forward PE are 17.05 and 17.36, respectively. While those metrics have risen for the company since the beginning of the year, they are justified by its prospects in the AD market, making Biogen's stock a buy right now.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-21 19:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/2-top-biotech-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing in biotechnology companies can be a risky proposition. Regulatory setbacks or negative results from clinical trials are sometimes enough to send shares falling off a cliff. But biotech ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/2-top-biotech-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司","VTNR":"顶点能源"},"source_url":"https://www.fool.com/investing/2021/07/21/2-top-biotech-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153643536","content_text":"Investing in biotechnology companies can be a risky proposition. Regulatory setbacks or negative results from clinical trials are sometimes enough to send shares falling off a cliff. But biotech companies can also offer explosive growth, provided you pick the right ones. And before investing in a biotech company, it's essential to look at the financial opportunity offered by its current lineup of products (or most promising pipeline candidates), both in the short and long run.\nTwo biotechs whose lead products offer great potential are Vertex Pharmaceuticals (NASDAQ:VRTX) and Biogen (NASDAQ:BIIB). Let's see why both of these companies are worth investing in today.\n\nImage source: Getty Images.\n1. Vertex Pharmaceuticals\nBiotech giant Vertex Pharmaceuticals focuses on developing treatments for rare diseases. The company is best known for its suite of medicines that treat cystic fibrosis (CF), a potentially deadly genetic condition that affects a patient's internal organs, including the lungs and the digestive system. CF affects 75,000 people in the U.S., Australia, and Europe, and there are 1,000 new cases diagnosed in the U.S. every year.\nBecause there are more than 100 mutations of the gene that causes CF, it's been hard to develop a single medicine that can treat the entirety of this patient population. However, back in October 2019, the U.S. Food and Drug Administration (FDA) approved Vertex's Trikafta, a therapy that can treat up to 90% of CF patients.\nLast year, Trikafta generated $3.9 billion in sales and that number will rise to $8.7 billion in 2026, according to the research company Evaluate Pharma, making it among the 10 best-selling drugs in the world. With that said, there are other reasons why Vertex Pharma is a buy.\nThe company boasts several exciting pipeline programs, including CTX001, a gene-editing therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia that it's developing in collaboration with CRISPR Therapeutics. If CTX001 earns regulatory approval, it would be a major achievement since there are currently few therapy options for those two blood-related disorders. The ones that exist (including stem cell transplants) are rife with risks.\nCTX001 has shown the ability to eliminate the need for blood transfusions in TDT patients up to 26 months after treatment. It has also successfully freed SCD patients of painful side effects of the illness called vaso-occlusive crises, up to 22 months post-treatment.\nDuring the company's first-quarter earnings conference call, Vertex CEO Reshma Kewalramani said that a regulatory submission for CTX001 \"may be possible in the next 18 to 24 months.\" Vertex Pharma does have other pipeline candidates, and the company generated a little more than $3 billion in free cash flow over the past year, allowing it to acquire more promising programs from other biotechs if necessary.\nLastly, now is an excellent time to buy this stock because it has severely underperformed of late. Shares of Vertex Pharma are down 34% in the past year, while the S&P 500 is up by 31% in the same period. Vertex's current price-to-earnings (PE) ratio is 19.06 -- which is about as low as it has been in two years -- and its forward PE stands at 18.39, which is also low by its standards. At current levels, this biotech stock is definitely a buy.\n\nImage source: Getty Images.\n2. Biogen\nBiogen's prospects didn't seem so great just 12 months ago. In June 2020, a judge invalidated a patent on Biogen's multiple sclerosis (MS) drug Tecfidera. The company has been facing biosimilar competition for this product since the second half of 2020, and its sales have declined quite a bit as a result.\nLast year, it also seemed unlikely that Biogen's drug for Alzheimer's disease (AD) Aduhelm (aducanumab) would earn regulatory approval since an independent panel convened by the FDA almost unanimously voted against giving the drug the green light.\nBut against all odds, Aduhelm did earn regulatory approval, and although Tecfidera's prospects haven't changed, the AD drug alone is enough to brighten Biogen's future significantly. Note that Aduhelm is the first AD drug approved by the FDA since 2003, and it is also the first of its kind to target one of the rumored causes of this invasive illness: the accumulation of beta-amyloid protein in the brain.\nIt won't be cheap; the cost of a one-year course for the treatment will be $56,000. There are 6 million AD patients in the U.S., but the FDA emphasized that Aduhelm should be prescribed to patients with \"mild cognitive impairment or mild dementia stage of disease.\"\nEven so, Aduhelm is likely to rack up well over $1 billion in sales within the next couple of years. Biogen has many more pipeline programs, including half a dozen in late-stage studies. There is no doubt the company will look to diversify its revenue source away from Aduhelm in the coming years.\nAnd even though the biotech's shares have already benefited from the approval of the AD drug -- with its stock up by 34.1% year to date -- I believe there is significant upside left for the company, especially once sales of Aduhelm start coming in.\nBiogen's PE and forward PE are 17.05 and 17.36, respectively. While those metrics have risen for the company since the beginning of the year, they are justified by its prospects in the AD market, making Biogen's stock a buy right now.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":176379317,"gmtCreate":1626867372839,"gmtModify":1703479539372,"author":{"id":"3578109783162616","authorId":"3578109783162616","name":"wwwwwl","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578109783162616","authorIdStr":"3578109783162616"},"htmlText":"Vertex!!","listText":"Vertex!!","text":"Vertex!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/176379317","repostId":2153643536,"repostType":4,"repost":{"id":"2153643536","kind":"highlight","pubTimestamp":1626866940,"share":"https://ttm.financial/m/news/2153643536?lang=&edition=fundamental","pubTime":"2021-07-21 19:29","market":"us","language":"en","title":"2 Top Biotech Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2153643536","media":"Motley Fool","summary":"Both of these companies have successfully developed breakthrough medicines.","content":"<p>Investing in biotechnology companies can be a risky proposition. Regulatory setbacks or negative results from clinical trials are sometimes enough to send shares falling off a cliff. But biotech companies can also offer explosive growth, provided you pick the right ones. And before investing in a biotech company, it's essential to look at the financial opportunity offered by its current lineup of products (or most promising pipeline candidates), both in the short and long run.</p>\n<p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> biotechs whose lead products offer great potential are <b><a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals</a></b> (NASDAQ:VRTX) and <b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b> (NASDAQ:BIIB). Let's see why both of these companies are worth investing in today.</p>\n<p><img src=\"https://static.tigerbbs.com/1e68b2bfcc71824b55ac1ca69d2eed8b\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>1. <a href=\"https://laohu8.com/S/VTNR\">Vertex</a> Pharmaceuticals</h3>\n<p>Biotech giant Vertex Pharmaceuticals focuses on developing treatments for rare diseases. The company is best known for its suite of medicines that treat cystic fibrosis (CF), a potentially deadly genetic condition that affects a patient's internal organs, including the lungs and the digestive system. CF affects 75,000 people in the U.S., Australia, and Europe, and there are 1,000 new cases diagnosed in the U.S. every year.</p>\n<p>Because there are more than 100 mutations of the gene that causes CF,&nbsp;it's been hard to develop a single medicine that can treat the entirety of this patient population. However, back in October 2019, the U.S. Food and Drug Administration (FDA) approved Vertex's Trikafta, a therapy that can treat up to 90% of CF patients.</p>\n<p>Last year, Trikafta generated $3.9 billion in sales and that number will rise to $8.7 billion in 2026, according to the research company Evaluate Pharma, making it among the 10 best-selling drugs in the world. With that said, there are other reasons why Vertex Pharma is a buy.</p>\n<p>The company boasts several exciting pipeline programs, including CTX001, a gene-editing therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia that it's developing in collaboration with <b>CRISPR Therapeutics</b>. If CTX001 earns regulatory approval, it would be a major achievement since there are currently few therapy options for those two blood-related disorders. The ones that exist (including stem cell transplants) are rife with risks.</p>\n<p>CTX001 has shown the ability to eliminate the need for blood transfusions in TDT patients up to 26 months after treatment. It has also successfully freed SCD patients of painful side effects of the illness called vaso-occlusive crises, up to 22 months post-treatment.</p>\n<p>During the company's first-quarter earnings conference call, Vertex CEO Reshma Kewalramani said that a regulatory submission for CTX001 \"may be possible in the next 18 to 24 months.\" Vertex Pharma does have other pipeline candidates, and the company generated a little more than $3 billion in free cash flow over the past year, allowing it to acquire more promising programs from other biotechs if necessary.</p>\n<p>Lastly, now is an excellent time to buy this stock because it has severely underperformed of late. Shares of Vertex Pharma are down 34% in the past year, while the <b>S&amp;P 500</b> is up by 31% in the same period. Vertex's current price-to-earnings (PE) ratio is 19.06 -- which is about as low as it has been in two years -- and its forward PE stands at 18.39, which is also low by its standards. At current levels, this biotech stock is definitely a buy.</p>\n<p><img src=\"https://static.tigerbbs.com/198a83aa9d0f757fa77165d137b17531\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>2. Biogen</h3>\n<p>Biogen's prospects didn't seem so great just 12 months ago. In June 2020, a judge invalidated a patent on Biogen's multiple sclerosis (MS) drug Tecfidera. The company has been facing biosimilar competition for this product since the second half of 2020, and its sales have declined quite a bit as a result.</p>\n<p>Last year, it also seemed unlikely that Biogen's drug for Alzheimer's disease (AD) Aduhelm (aducanumab) would earn regulatory approval since an independent panel convened by the FDA almost unanimously voted against giving the drug the green light.</p>\n<p>But against all odds, Aduhelm did earn regulatory approval, and although Tecfidera's prospects haven't changed, the AD drug alone is enough to brighten Biogen's future significantly. Note that Aduhelm is the first AD drug approved by the FDA since 2003, and it is also the first of its kind to target <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the rumored causes of this invasive illness: the accumulation of beta-amyloid protein in the brain.</p>\n<p>It won't be cheap; the cost of a <a href=\"https://laohu8.com/S/AONE.U\">one</a>-year course for the treatment will be $56,000. There are 6 million AD patients in the U.S., but the FDA emphasized that Aduhelm should be prescribed to patients with \"mild cognitive impairment or mild dementia stage of disease.\"</p>\n<p>Even so, Aduhelm is likely to rack up well over $1 billion in sales within the next couple of years. Biogen has many more pipeline programs, including half a dozen in late-stage studies.&nbsp;There is no doubt the company will look to diversify its revenue source away from Aduhelm in the coming years.</p>\n<p>And even though the biotech's shares have already benefited from the approval of the AD drug -- with its stock up by 34.1% year to date -- I believe there is significant upside left for the company, especially once sales of Aduhelm start coming in.</p>\n<p>Biogen's PE and forward PE are 17.05 and 17.36, respectively. While those metrics have risen for the company since the beginning of the year, they are justified by its prospects in the AD market, making Biogen's stock a buy right now.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Biotech Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Biotech Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-21 19:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/2-top-biotech-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing in biotechnology companies can be a risky proposition. Regulatory setbacks or negative results from clinical trials are sometimes enough to send shares falling off a cliff. But biotech ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/2-top-biotech-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司","VTNR":"顶点能源"},"source_url":"https://www.fool.com/investing/2021/07/21/2-top-biotech-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153643536","content_text":"Investing in biotechnology companies can be a risky proposition. Regulatory setbacks or negative results from clinical trials are sometimes enough to send shares falling off a cliff. But biotech companies can also offer explosive growth, provided you pick the right ones. And before investing in a biotech company, it's essential to look at the financial opportunity offered by its current lineup of products (or most promising pipeline candidates), both in the short and long run.\nTwo biotechs whose lead products offer great potential are Vertex Pharmaceuticals (NASDAQ:VRTX) and Biogen (NASDAQ:BIIB). Let's see why both of these companies are worth investing in today.\n\nImage source: Getty Images.\n1. Vertex Pharmaceuticals\nBiotech giant Vertex Pharmaceuticals focuses on developing treatments for rare diseases. The company is best known for its suite of medicines that treat cystic fibrosis (CF), a potentially deadly genetic condition that affects a patient's internal organs, including the lungs and the digestive system. CF affects 75,000 people in the U.S., Australia, and Europe, and there are 1,000 new cases diagnosed in the U.S. every year.\nBecause there are more than 100 mutations of the gene that causes CF, it's been hard to develop a single medicine that can treat the entirety of this patient population. However, back in October 2019, the U.S. Food and Drug Administration (FDA) approved Vertex's Trikafta, a therapy that can treat up to 90% of CF patients.\nLast year, Trikafta generated $3.9 billion in sales and that number will rise to $8.7 billion in 2026, according to the research company Evaluate Pharma, making it among the 10 best-selling drugs in the world. With that said, there are other reasons why Vertex Pharma is a buy.\nThe company boasts several exciting pipeline programs, including CTX001, a gene-editing therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia that it's developing in collaboration with CRISPR Therapeutics. If CTX001 earns regulatory approval, it would be a major achievement since there are currently few therapy options for those two blood-related disorders. The ones that exist (including stem cell transplants) are rife with risks.\nCTX001 has shown the ability to eliminate the need for blood transfusions in TDT patients up to 26 months after treatment. It has also successfully freed SCD patients of painful side effects of the illness called vaso-occlusive crises, up to 22 months post-treatment.\nDuring the company's first-quarter earnings conference call, Vertex CEO Reshma Kewalramani said that a regulatory submission for CTX001 \"may be possible in the next 18 to 24 months.\" Vertex Pharma does have other pipeline candidates, and the company generated a little more than $3 billion in free cash flow over the past year, allowing it to acquire more promising programs from other biotechs if necessary.\nLastly, now is an excellent time to buy this stock because it has severely underperformed of late. Shares of Vertex Pharma are down 34% in the past year, while the S&P 500 is up by 31% in the same period. Vertex's current price-to-earnings (PE) ratio is 19.06 -- which is about as low as it has been in two years -- and its forward PE stands at 18.39, which is also low by its standards. At current levels, this biotech stock is definitely a buy.\n\nImage source: Getty Images.\n2. Biogen\nBiogen's prospects didn't seem so great just 12 months ago. In June 2020, a judge invalidated a patent on Biogen's multiple sclerosis (MS) drug Tecfidera. The company has been facing biosimilar competition for this product since the second half of 2020, and its sales have declined quite a bit as a result.\nLast year, it also seemed unlikely that Biogen's drug for Alzheimer's disease (AD) Aduhelm (aducanumab) would earn regulatory approval since an independent panel convened by the FDA almost unanimously voted against giving the drug the green light.\nBut against all odds, Aduhelm did earn regulatory approval, and although Tecfidera's prospects haven't changed, the AD drug alone is enough to brighten Biogen's future significantly. Note that Aduhelm is the first AD drug approved by the FDA since 2003, and it is also the first of its kind to target one of the rumored causes of this invasive illness: the accumulation of beta-amyloid protein in the brain.\nIt won't be cheap; the cost of a one-year course for the treatment will be $56,000. There are 6 million AD patients in the U.S., but the FDA emphasized that Aduhelm should be prescribed to patients with \"mild cognitive impairment or mild dementia stage of disease.\"\nEven so, Aduhelm is likely to rack up well over $1 billion in sales within the next couple of years. Biogen has many more pipeline programs, including half a dozen in late-stage studies. There is no doubt the company will look to diversify its revenue source away from Aduhelm in the coming years.\nAnd even though the biotech's shares have already benefited from the approval of the AD drug -- with its stock up by 34.1% year to date -- I believe there is significant upside left for the company, especially once sales of Aduhelm start coming in.\nBiogen's PE and forward PE are 17.05 and 17.36, respectively. While those metrics have risen for the company since the beginning of the year, they are justified by its prospects in the AD market, making Biogen's stock a buy right now.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5282615,"gmtCreate":1626868070940,"gmtModify":1663231264234,"authorId":3579758808989513,"author":{"id":3579758808989513,"idStr":"3579758808989513","authorId":3579758808989513,"name":"ACCY","avatar":"https://static.tigerbbs.com/a44626552831eb06aa01cf85dcaf7422","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":176379317,"type":1,"supId":0,"prevId":0,"content":"Wow","text":"Wow","html":"Wow"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":50,"commentSize":5,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}